Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
Eric Volkman, The Motley FoolTue, April 28, 2026 at 11:30 PM UTC
0
Key Points -
Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period.
More is to come, apparently, as management raised its net sales guidance for the drug.
10 stocks we like better than Kiniksa Pharmaceuticals International ›
Kiniksa Pharmaceuticals International (NASDAQ: KNSA) was quite a hit on our domestic stock exchange in Tuesday's trading session. It released its inaugural 2026 earnings report and, with key fundamentals that beat analyst estimates, grateful investors rushed into the stock, lifting it by almost 24% that day.
Long-tail success
Kiniksa, a commercial-stage biotech targeting afflictions with significant unmet need, published its first-quarter figures Tuesday morning. This revealed that revenue, comprised entirely of sales of multi-indication drug Arcalyst, rose to over $214 million from the year-ago tally of under $138 million.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Person checking medicine on a shelf in a pharmacy.
Image source: Getty Images.
Net income under generally accepted accounting principles (GAAP), meanwhile, more than doubled to $22.6 million from first quarter 2025's $8.5 million ($0.27 per share).
Both headline figures convincingly beat the consensus analyst estimates. Pundits tracking Kiniksa stock were collectively modeling slightly over $207 million for revenue and $0.21 per share for GAAP bottom-line profitability.
Kiniksa pointed to Arcalyst's success with its most recent approval, specifically for heart disorder pericarditis, as the driver of its recent popularity. This inspired management to raise its forecast for the drug's net sales this year to $930 million to $945 million. Previously, it had forecast $900 million to $920 million.
Advertisement
Positive indications
While I tend to be wary of commercial-stage biotechs with only one product on pharmacy shelves, over the years, Arcalyst has proven to be quite versatile. I'd expect it to collect approvals for other indications, too, as it is also being investigated by Kiniksa for other afflictions. So in the end, I'd be bullish on Kiniksa's prospects.
Should you buy stock in Kiniksa Pharmaceuticals International right now?
Before you buy stock in Kiniksa Pharmaceuticals International, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Kiniksa Pharmaceuticals International wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $492,752!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,327,935!*
Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 28, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kiniksa Pharmaceuticals International, Plc. The Motley Fool has a disclosure policy.
Source: “AOL Money”
